Mitochondrial diseases are genetic disorders caused by dysfunction of the mitochondrial respiratory chain, leading to impaired energy production. This comparison matrix focuses on the overlap between mitochondrial diseases and neurodegenerative disorders, particularly examining Leigh syndrome, MELAS syndrome, and [Parkinson's Disease](/diseases/parkinsons-disease-disease).
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|----------------|----------------|---------------------|
| Acronym | - | Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes | - |
| Inheritance | Maternal (mtDNA) or nuclear DNA | Maternal (mtDNA) | Usually complex, some familial |
| Primary Defect | Pyruvate dehydrogenase complex, respiratory chain complexes | Mitochondrial tRNA mutation (m.3243A>G) | Complex I deficiency, mitochondrial dysfunction |
| Onset Age | Early childhood (infancy-juvenile) | Childhood to young adult | Adult (60-70 years) |
| Prognosis | Usually fatal in childhood | Variable, stroke-like episodes | Chronic, 10-20 year course |
Mitochondrial diseases are genetic disorders caused by dysfunction of the mitochondrial respiratory chain, leading to impaired energy production. This comparison matrix focuses on the overlap between mitochondrial diseases and neurodegenerative disorders, particularly examining Leigh syndrome, MELAS syndrome, and [Parkinson's Disease](/diseases/parkinsons-disease-disease).
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|----------------|----------------|---------------------|
| Acronym | - | Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes | - |
| Inheritance | Maternal (mtDNA) or nuclear DNA | Maternal (mtDNA) | Usually complex, some familial |
| Primary Defect | Pyruvate dehydrogenase complex, respiratory chain complexes | Mitochondrial tRNA mutation (m.3243A>G) | Complex I deficiency, mitochondrial dysfunction |
| Onset Age | Early childhood (infancy-juvenile) | Childhood to young adult | Adult (60-70 years) |
| Prognosis | Usually fatal in childhood | Variable, stroke-like episodes | Chronic, 10-20 year course |
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|---------------|----------------|---------------------|
| Core Symptoms | Encephalopathy, basal ganglia lesions, respiratory failure | Encephalopathy, lactic acidosis, stroke-like episodes | Tremor, bradykinesia, rigidity |
| Neurological | Developmental regression, hypotonia, dystonia | Seizures, migraine-like headaches, cognitive decline | Resting tremor, gait disturbance |
| Movement Disorders | Dystonia, choreoathetosis | Rare | Resting tremor, bradykinesia, rigidity |
| Cognitive | Developmental delay, intellectual disability | Progressive cognitive decline | Late-stage dementia (PDD) |
| Seizures | Common | Common (80%) | Rare |
| Stroke-like Episodes | Rare | Core feature | Not a feature |
| Visual Loss | Optic atrophy | Rare | Usually not |
| Hearing Loss | Sensorineural hearing loss common | Sensorineural hearing loss common | Usually not |
| Cardiac | Hypertrophic cardiomyopathy | Hypertrophic cardiomyopathy, conduction defects | Usually not |
| Endocrine | Growth failure, diabetes | Diabetes mellitus | Not a feature |
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|---------------|----------------|---------------------|
| Primary Gene(s) | [NDUFS1](/genes/ndufs1), [NDUFS4](/genes/ndufs4), [NDUFAF6](/genes/ndufaf6), [SURF1](/genes/surf1), [MTATP6](/genes/mtATP6) | [MT-TL1](/genes/mtTL1), m.3243A>G | [SNCA](/genes/snca), [LRRK2](/genes/lrrk2), [PARKIN](/genes/parkin), [PINK1](/genes/pink1), [DJ-1](/genes/dj1), [GBA](/genes/gba) |
| Inheritance | Maternal or autosomal recessive | Maternal only | Complex, some autosomal dominant |
| Mutation Type | Point mutations, deletions | Point mutation (m.3243A>G) | Point mutations, duplications |
| Mitochondrial Function | Complex I, IV, V deficiency | Impaired protein synthesis, Complex I deficiency | Complex I deficiency |
| mtDNA Copy Number | Reduced | Reduced | May be reduced |
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|---------------|----------------|---------------------|
| Key Lesions | Symmetric basal ganglia necrosis | Focal cortical necrosis, stroke-like lesions | Substantia nigra dopaminergic neuron loss |
| Location | Basal ganglia, brainstem | [Cortex](/brain-regions/cortex), especially occipital | Substantia nigra, Lewy bodies |
| Vulnerable Regions | Putamen, caudate, thalamus | Posterior cortex, especially occipital | Substantia nigra pars compacta |
| Inclusions | No specific inclusions | Ragged-red fibers | Lewy bodies (alpha-synuclein) |
| Neuronal Loss | Basal ganglia, brainstem | Cortical [neurons](/entities/neurons) | Dopaminergic neurons |
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|---------------|----------------|---------------------|
| ATP Production | Severely impaired | Moderately impaired | Impaired in substantia nigra |
| Complexes Affected | I, III, IV, V | I (primary) | I deficiency prominent |
| Lactic Acidosis | Present, especially during crises | Persistent | May be mild |
| Glucose Metabolism | Impaired | Impaired | Variable |
| Oxidative Stress | High | High | High in PD |
| Mitochondrial Biogenesis | Reduced | Reduced | PGC-1α pathway disrupted |
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|---------------|----------------|---------------------|
| Primary Treatment | Supportive care, ketogenic diet | L-arginine, supportive care | Levodopa, dopamine agonists |
| Disease-Modifying | None | None | None approved |
| Metabolic Interventions | Dichloroacetate, thiamine, riboflavin | CoQ10, L-arginine, B vitamins | CoQ10 (some benefit) |
| Antioxidants | May help | May help | May help |
| Physical Therapy | Supportive | Supportive | Essential for mobility |
| Seizure Control | Antiepileptics | Antiepileptics | Not typically needed |
| Feature | Leigh Syndrome | MELAS Syndrome | Parkinson's Disease |
|---------|---------------|----------------|---------------------|
| Lactate | Elevated (especially CSF) | Elevated (blood and CSF) | Variable, can be mildly elevated |
| Pyruvate | Elevated | Elevated | Normal |
| CSF | Elevated lactate, elevated glycine | Elevated lactate | Usually normal |
| Muscle Biopsy | Ragged-red fibers possible | Ragged-red fibers (80%) | Not diagnostic |
| Imaging | Basal ganglia lesions | Cortical stroke-like lesions | DaTscan: reduced uptake |
| Mechanism | Leigh/MELAS | Parkinson's Disease |
|-----------|-------------|-------------------|
| Oxidative stress | High | High |
| Impaired mitophagy | Yes | Yes |
| Complex I deficiency | Yes | Yes |
| Neuronal energy failure | Yes | Yes |
| [Apoptosis](/entities/apoptosis) susceptibility | Yes | Yes |
| Condition | Mitochondrial Gene | Neurological Features |
|-----------|-------------------|----------------------|
| Leigh Syndrome | [MT-ATP6](/genes/mtATP6), [NDUFS1](/genes/ndufs1) | Basal ganglia disease, developmental regression |
| MELAS | [MT-TL1](/genes/mtTL1) | Stroke-like episodes, seizures, cognitive decline |
| LHON | [MT-ND1](/genes/mtND1), [MT-ND4](/genes/mtND4) | Optic neuropathy |
| MERRF | [MT-TK](/genes/mtTK) | Myoclonus, seizures, ataxia |
| KSS | mtDNA deletions | External ophthalmoplegia, cardiac conduction |
| [MPAN](/diseases/mpan) | [C19orf12](/genes/c19orf12) | Spastic paraplegia, neurodegeneration |